Foundation Medicine Inc (FMI) reported quarterly earnings results on Tuesday, Aug-2-2016. The company reported $-0.84 earnings per share for the quarter, missing the analyst consensus estimate by $-0.05. Analysts had a consensus of $-0.79. The company posted revenue of $28.24 million in the period, compared to analysts expectations of $26.72 million. The company’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.98 EPS.
Foundation Medicine Inc closed down -0.09 points or -0.38% at $23.37 with 1,14,621 shares getting traded on Friday. Post opening the session at $23.36, the shares hit an intraday low of $23.1 and an intraday high of $23.8899 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Jul 6, 2016, David Daly (Chief Commercial Officer) sold 5,008 shares at $17.83 per share price. According to the SEC, on Jul 6, 2016, Jason Ryan (Chief Financial Officer) sold 4,687 shares at $17.83 per share price. On Jul 6, 2016, Michael J Pellini (Chief Executive Officer) sold 10,160 shares at $17.83 per share price, according to the Form-4 filing with the securities and exchange commission.
Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.